References
- Zelis R, Flaim S F. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 1982; 24: 437–59
- Francis G S, Goldsmith S R, Levine T B, Olivari M T, Cohn J N. The neurohumoral axis in congestive heart failure. Ann Int Med 1984; 101: 370–7
- Creager M A, Faxon D P, Cutler S S, Kohlmann O, Ryan T J, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin svstem and the sympathetic nervous system. J Am Coll Cardiol 1986; 7: 758–65
- Goldstein D S. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol 1981; 48: 1147–54
- Cohn J N, Levine T B, Olivari M T, Garberg V, Lura D, Francis G S, Simon A B, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eingl J Med 1984; 311: 819–23
- Westheim A, Os I, Thaulow E, Kjeldsen S E, Eritsland J, Eide I K. Haemodynamic and neurohumoral effects of cold pressor test in severe heart failure. Clin Physiol 1992; 12: 95–106
- Gottlieb S S, Kukin M L, Ahem D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13: 1534–9
- McMurray J J, Ray S G, Abdullah I, Dargie H J, Morton J J. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374–9
- Rodeheffer R J, Lerman A, Heublein D M, Burnett J C, Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992; 67: 719–24
- Pernow J, Lundberg J M, Kaijser L, Hjemdahl P, Theodorsson-Norheim E, Martinsson A, Pernow B. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986; 6: 561–78
- Andreasen F, Mikkelsen E. Distribution elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 1977; 12: 15–22
- The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
- Lowe J, Gray J, Henry D A, Lawson D H. Adverse reactions to furosemide in hospital inpatients. Br Med J 1979; 2: 360–2
- Gallagher K L, Jones J K. Furosemide-induced ototoxicity. Ann Int Med 1979; 91: 744–5
- Gerlag P GG, Van Meijel J JM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Int Med 1988; 148: 286–91
- Van Meyel J JM, Smits P, Dormans T, Gerlag P GG, Russel F GM, Gribnau F WJ. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Int Med 1994; 235: 329–34
- Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17–22
- Francis G S, Siegel R M, Goldsmith S R, Olivari M T, Levine T B, Cohn J N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Int Med 1985; 103: 1–6
- Lahav M, Regev A, Ra'anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102: 725–31
- Dormans T PJ, Van Meyel J JM, Gerlag P GG, Tan Yen, Russel F GM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376–82